Auscann Group Holdings Ltd (AC8)

Sydney
0.040
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.040/0.041
  • Day's Range:
    0.040 - 0.042

AC8 Overview

Prev. Close
0.042
Day's Range
0.04-0.042
Revenue
1.13M
Open
0.042
52 wk Range
0.035-0.089
EPS
-0.06
Volume
0
Market Cap
17.62M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
189,555
P/E Ratio
-0.67
Beta
1.46
1-Year Change
-48.05%
Shares Outstanding
440,547,110
Next Earnings Date
-
What is your sentiment on Auscann Group?
or
Market is currently closed. Voting is open during market hours.

Auscann Group Holdings Ltd News

Auscann Group Holdings Ltd Analysis

Auscann Group Holdings Ltd Company Profile

Auscann Group Holdings Ltd Company Profile

Employees
0
Market
Australia

AusCann Group Holdings Limited is an Australia-based company, which is focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Neuvis is its controlled-dose technology platform, which delivers cannabinoids (CBD) to human patients, with the first product in the range being a THC:CBD hard-shell capsule in a 1:1 ratio, in both a 2.5mg and 10mg strength. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol and cannabidiol whole plant extracts in a ratio to target pain and inflammation in dogs. DermaCann is its CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. MicroMAX is an encapsulation technology, which helps to enhance the delivery of cannabis-based animal health products. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary